Navigation Links
R&J Public Relations Named Agency of Record for Aerocrine, Inc.

BRIDGEWATER, N.J., Jan. 25, 2011 /PRNewswire/ -- Aerocrine, Inc., an innovative medical technology company focused on the treatment of patients with inflamed airways, has selected R&J Public Relations, LLC of Bridgewater, N.J., as its public relations agency of record.  R&J will conduct strategic public relations for the Aerocrine brand; most immediately surrounding the NIOX MINO®, the first and only hand-held device available to measure exhaled nitric oxide (eNO) to aid in asthma management in the United States.

For the first time ever, The NIOX MINO provides doctors the ability to more effectively diagnose, monitor and optimize therapy for individuals suffering from inflammatory airway diseases through one easy-to-use device.  This ground-breaking technology helps eliminate the uncertainties that contribute to asthma morbidity and mortality, including incorrect diagnosis, patient adherence issues, and identifying those patients that will be responsive to treatment.

"Our comprehensive experience and strong presence in the healthcare market space combined with our aggressive and proactive consumer and media relations practices will provide Aerocrine with the leverage they need to elevate their innovative brand and products," said Scott Marioni, Executive Vice President of R&J Public Relations.  "R&J is confident that our strategic public relations will significantly increase the awareness of the Aerocrine brand and NIOX MINO while positioning eNO testing as a standard for patients with asthmatic symptoms."

The founders of Aerocrine originated from the Karolinska Institute in Sweden where they first discovered the significant tie between nitric oxide (NO) and inflammation.  Aerocrine used this discovery as a basis for creating products that assist in the management and care of people afflicted with varying airway inflammatory diseases.

R&J's main objective is to promptly elevate Aerocrine's brand through its established world-wide reputation, and further the awareness of Aerocrine's NIOX MINO products among allergists, pulmonologists, and potential patients. Through a decisive, long-term plan, combined with steadfast public and media relations efforts, R&J will support Aerocrine's growth and product-specific goal.

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. More information can be found online at

About R&J Public Relations

R&J Public Relations, LLC is a full-service public relations firm that consistently achieves superior results for a strong and diverse client base that ranges from divisions of large, multi-national conglomerates to regional market leaders.  Based in Bridgewater, N.J., with an office in Manhattan, the company has become one of the most respected, admired and prestigious PR agencies in the Greater New York/New Jersey region.  R&J has earned numerous awards for its strategic communications programs and was named a "Top Place to Work in PR" by PR News in 2010. For more information on R&J Public Relations, please visit

SOURCE R&J Public Relations, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Prices Public Offering of Common Stock
2. Pharmasset Announces Proposed Public Offering of Common Stock
3. Pharmacists Offer Recommendations to Guide Public Through Cold and Flu Season
4. American Scientific Resources, Inc. Announces S-1 Registration Statement Effective; Commences Public Reporting Requirements
5. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
6. FDA Warns Public of Continued Extortion Scam By FDA Impersonators
7. Amarin Prices Public Offering of American Depositary Shares
8. Dr. Marianne T. Sweetser Recognized by Strathmores Whos Who Worldwide Publication
9. HeartWare International, Inc. Announces Completion of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
10. Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
11. Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal
Post Your Comments:
(Date:10/10/2017)... 10, 2017   West Pharmaceutical Services, Inc. ... injectable drug administration, today shared the results of a ... improving the intradermal administration of polio vaccines. The study ... in May 2017 by Dr. Ondrej Mach , ... Health Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... The Rebound mobile app is poised to become a vital ... prescription drug addiction. The app empowers users to develop an ... their dosage in a safe, controlled manner while maximizing well-being. ... 100,000 people to sign up will enjoy 3 months of ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
Breaking Medicine News(10 mins):